Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-06-18

Initiative on Optimizing Malaria Vaccine Lab Assays Evaluation

Objective

A broad-range of candidate malaria vaccines derived from diverse novel technologies have resulted from the multiple approaches being taken by different groups in developing malaria vaccines. The majority of the candidates are recombinant proteins based on complex native antigens found on the surface of the parasite. Vaccine potential of these parasite surface antigens is often supported by epidemiological data, and by the ability to induce specific antibodies or potential protective responses in animals and later, in humans. Individual groups have developed assays within the context of the vaccine discovery efforts, with identification of measurable processes for parasite growth and virulence to test specific antigens. In-house assays are strain, stage and even process specific and the ability to compare results between different candidates is further limited by diverse methodologies and assay components such as parasites, cells and reagents. The absence of some level of harmonization of practices also makes interpreting the meaning and relevance of vaccine research outcomes complex. Lack of an enabling environment for comparability of research results generated in different labs could unfortunately lead to scepticism of the results that in turn generate uncertainty about the efficacy of the vaccines and rationale of the development pathway. To compare the relative merits of different candidate vaccines and approaches in a credible and informed manner, efforts must be made to create this enabling environment by supporting the development of a baseline level of standardization around key assays that can be utilized a) in the evaluation of malaria vaccines, and b) throughout the Development process. Consistent, reproducible and comparable intra- and inter-lab performance and increased accuracy and precision of assay data, will strengthen the quality of the data on vaccine performance and generate greater confidence in the vaccine potential of the candidate.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

FP7-HEALTH-2007-B
See other projects for this call

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

CSA-CA - Coordination (or networking) actions

Coordinator

EUROPEAN VACCINE INITIATIVE EWIV
EU contribution
€ 294 512,11
Address
VOSSSTRASSE 2 GEB 4040
69115 Heidelberg
Germany

See on map

Region
Baden-Württemberg Karlsruhe Heidelberg, Stadtkreis
Activity type
Research Organisations
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Participants (13)

My booklet 0 0